T1	intervention 99 109	exemestane
T2	location 375 381	Canada
T3	outcome 188 228	reduced invasive breast cancer incidence
T4	intervention-value 232 235	65%
T5	No-of-participants 242 247	4,560
T6	control 331 338	placebo
T7	outcome 1800 1812	discontinued
T8	intervention-value 1765 1768	32%
T9	control-value 1795 1798	28%
T10	intervention-value 1579 1581	8%
T11	intervention-value 1615 1617	4%
T12	outcome 1524 1540	worsening of QOL
T13	outcome 1263 1322	self-reported vasomotor symptoms, sexual symptoms, and pain
T14	outcome-Measure 510 551	Menopause-specific and health-related QOL
